{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T22:02:44Z","timestamp":1780005764038,"version":"3.53.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijgc.2025.102839","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T00:27:07Z","timestamp":1764980827000},"page":"102839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Feasibility of standard versus fractionated carboplatin-paclitaxel in older adults with ovarian cancer: a retrospective study"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7910-3744","authenticated-orcid":false,"given":"Elisabeth","family":"Ashton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Delanoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8826-7115","authenticated-orcid":false,"given":"Rym","family":"El Gharib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrien","family":"Rochand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Gervais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Nicaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Koual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Aza\u00efs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Sophie","family":"Bats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrica","family":"Bentivegna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laure","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Gisselbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Paillaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraya","family":"Mebarki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijgc.2025.102839_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.ijgc.2025.102839_bib4","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/IGC.0000000000000418","article-title":"Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study","volume":"25","author":"Sabatier","year":"2015","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102839_bib5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1200\/JCO.2002.20.1.173","article-title":"Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study","volume":"20","author":"Sundararajan","year":"2002","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102839_bib6","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1006\/gyno.2002.6759","article-title":"Age contrasts in clinical characteristics and pattern of care in patients with epithelial ovarian cancer","volume":"86","author":"Bruchim","year":"2002","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2025.102839_bib7","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.ygyno.2004.04.022","article-title":"Effectiveness of platinum-based chemotherapy among elderly patients with advanced ovarian cancer","volume":"94","author":"Hershman","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102839_bib8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ygyno.2004.12.026","article-title":"The influence of age and co-morbidity on treatment and prognosis of ovarian cancer: a population-based study","volume":"97","author":"Maas","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102839_bib9","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ygyno.2005.04.037","article-title":"Treatment patterns by decade of life in elderly women (> or =70 years of age) with ovarian cancer","volume":"98","author":"Uyar","year":"2005","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102839_bib10","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1097\/IGC.0b013e31821bb700","article-title":"Gynecologic Cancer InterGroup. Clinical trials and treatment of the elderly diagnosed with ovarian cancer","volume":"21","author":"Freyer","year":"2011","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"10.1016\/j.ijgc.2025.102839_bib11","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1097\/IGC.0000000000001097","article-title":"Ovarian cancer in elderly patients: patterns of care and treatment outcomes according to age and modified frailty index","volume":"27","author":"Ferrero","year":"2017","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102839_bib12","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/ijgc-2018-000026","article-title":"Treatment decision-making in elderly women with ovarian cancer: an age-based comparison","volume":"29","author":"van Walree","year":"2019","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2025.102839_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231192397","article-title":"Ovarian cancer in the older patient: where are we now? What to do next?","volume":"15","author":"Rousseau","year":"2023","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102839_bib14","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1006\/gyno.2002.6631","article-title":"Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study","volume":"85","author":"Ceccaroni","year":"2002","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2025.102839_bib15","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ygyno.2008.01.001","article-title":"Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients","volume":"109","author":"Fader","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102839_bib16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.critrevonc.2007.12.005","article-title":"A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study","volume":"66","author":"Pignata","year":"2008","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102839_bib17","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0959-8049(00)00050-2","article-title":"Single agents should be administered in preference to combination chemotherapy for the treatment of patients over 70 years of age with advanced ovarian carcinoma","volume":"36","author":"Pignata","year":"2000","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.ijgc.2025.102839_bib18","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1001\/jamaoncol.2021.0696","article-title":"Efficacy and safety of first-line single-agent carboplatin vs carboplatin plus paclitaxel for vulnerable older adult women with ovarian cancer: a GINECO\/GCIG randomized clinical trial","volume":"7","author":"Falandry","year":"2021","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.ijgc.2025.102839_bib19","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1093\/annonc\/mdt360","article-title":"Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial","volume":"24","author":"Falandry","year":"2013","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102839_bib20","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1093\/annonc\/mdr587","article-title":"Screening older cancer patients: first evaluation of the G-8 geriatric screening tool","volume":"23","author":"Bellera","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijgc.2025.102839_bib21","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.1963.03060120024016","article-title":"Studies of illness in the aged","volume":"185","author":"Katz","year":"1963","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102839_bib22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/geront\/9.3_Part_1.179","article-title":"Assessment of older people: self-maintaining and Instrumental Activities of Daily Living","volume":"9","author":"Lawton","year":"1969","journal-title":"Gerontologist"},{"issue":"3","key":"10.1016\/j.ijgc.2025.102839_bib23","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ygyno.2016.11.033","article-title":"Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - an NRG oncology\/Gynecologic Oncology Group study","volume":"144","author":"von Gruenigen","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"9698","key":"10.1016\/j.ijgc.2025.102839_bib24","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","article-title":"Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial","volume":"374","author":"Katsumata","year":"2009","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ijgc.2025.102839_bib25","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1056\/NEJMoa1505067","article-title":"Weekly vs. Every-3-Week paclitaxel and carboplatin for Ovarian Cancer","volume":"374","author":"Chan","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ijgc.2025.102839_bib26","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(22)00283-2","article-title":"Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial","volume":"23","author":"Clamp","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2025.102839_bib27","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.ijgc.2025.102839_bib28","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ijgc.2025.102839_bib29","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.ijgc.2025.102839_bib30","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25019632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X25019632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T21:21:18Z","timestamp":1780003278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X25019632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1048891X25019632"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102839","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Feasibility of standard versus fractionated carboplatin-paclitaxel in older adults with ovarian cancer: a retrospective study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2025.102839","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102839"}}